Pre-made Enuzovimab benchmark antibody ( Whole mAb, anti-SARS-CoV-2 Spike RBD therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Enuzovimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.Enuzovimab is an anti-SARS-CoV-2 recombinant antibody engineered with specific sequences identified from the B cells of a COVID-19 convalescent patient. The antibody binds to the viral spike protein with high affinity and has demonstrated potent neutralization of live virus infections in vitro and in vivo.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-665-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Enuzovimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody
INN Name	Enuzovimab
Target	SARS-CoV-2 Spike RBD
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Active
100% SI Structure	7cjf:AB
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2021
Year Recommended	na
Companies	ABL Bio;HiFiBiO Therapeutics
Conditions Approved	na
Conditions Active	COVID-19
Conditions Discontinued	na
Development Tech	na